Pharmacokinetic evaluation of vortioxetine for the treatment of major depressive disorder

@article{Dubovsky2014PharmacokineticEO,
  title={Pharmacokinetic evaluation of vortioxetine for the treatment of major depressive disorder},
  author={Steven L. Dubovsky},
  journal={Expert Opinion on Drug Metabolism \& Toxicology},
  year={2014},
  volume={10},
  pages={759 - 766}
}
  • S. Dubovsky
  • Published 9 April 2014
  • Psychology
  • Expert Opinion on Drug Metabolism & Toxicology
Introduction: Major depressive disorder (MDD), one of the most common disorders in medical practice and one of the leading causes of disability worldwide, is frequently comorbid with anxiety disorders. Vortioxetine (Lu AA21004) is a new antidepressant that combines a number of neurotransmitter reuptake and receptor effects that have been thought to predict efficacy as a treatment for depressive and anxiety disorders. Areas covered: This review summarizes the pharmacology and neurobiology of… 

Criticisms of drugs in early development for the treatment of depression: what can be improved?

An updated overview of the progress and critical limitations in the development of novel antidepressants for major depressive disorder is provided.

Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder.

The results suggest that vortioxetine may be an effective treatment option for MDD, but they should be interpreted and translated into clinical practice with caution, as the meta-analysis was based on a limited number of heterogeneous RCTs.

Vortioxetine Disposition in Obesity: Potential Implications for Patient Safety

To avoid a potential risk of serotonin syndrome, obese patients who plan to change their medication from vortioxetine to a monoamine oxidase inhibitor (MAOI) should extend the time between vortoxetine discontinuation and MAOI initiation beyond what is recommended in the product label.

Depression and Anxiety Disorders

This is a concise and up to date overview of the epidemiology, physiopathology, comorbidity, diagnosis and treatment of depression and anxiety disorders.

Pharmacokinetics, Safety, and Tolerability of Vortioxetine Following Single‐ and Multiple‐Dose Administration in Healthy Japanese Adults

Overall, vortioxetine pharmacokinetics, safety, and tolerability in Japanese adults were comparable to reports in non‐Japanese populations.

What Is New about New Antidepressants?

  • S. Dubovsky
  • Psychology, Medicine
    Psychotherapy and Psychosomatics
  • 2018
How realistic this expectation of each new antidepressant that reaches the market will represent a conceptual and therapeutic advance over previous medications is determined if the validity of the assumptions that underlie the development of new antidepressants and the data supporting their differential effectiveness are reviewed.

TRATAMENTO FARMACOLÓGICO DA DEPRESSÃO PÓS-PARTO

A sertralina mostra-se como opcao para DPP, pelas baixas taxas de transferencia no leite materno, proporcionando menos riscos de efeitos adversos ao bebe.

Behandlung der Depression bei koronarer Herzerkrankung

An overview of the epidemiology of depression in CHD, the mechanisms of association and the current state of evidence with respect to the different treatment options is provided.

References

SHOWING 1-10 OF 42 REFERENCES

Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder

Vortioxetine demonstrated a favourable safety and tolerability profile and maintained effectiveness over 12 months of treatment, as with all open-label studies, the conclusions that can be drawn are limited by the lack of a placebo control.

Efficacy, safety and tolerability of Symbyax® for acute-phase management of treatment-resistant depression

The short-term effectiveness of OFC for TRD is supported by results of five published randomized, controlled, acute-phase studies of generally similar design, and, in each study, OFC was associated with rapid reduction in depressive symptoms.

Beyond the serotonin reuptake inhibitors: rationales for the development of new serotonergic agents.

  • S. Dubovsky
  • Psychology, Biology
    The Journal of clinical psychiatry
  • 1994
A new generation of drugs acting on specific 5-HT receptors has the advantage of a low frequency of adverse effects, applicability in mixed and complicated syndromes, and usefulness as probes of the psychobiology of mental disorders.

Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder

In this study, Lu AA21004 5 or 10 mg/day was efficacious in preventing relapse and was well tolerated in the maintenance treatment of GAD.

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

The response and remission rates in this highly generalizable sample with substantial axis I and axis III comorbidity closely resemble those seen in 8-week efficacy trials.

Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis.

Venlafaxine has greater efficacy than SSRIs although there is uncertainty in comparison with other antidepressants, and further studies are required to determine the clinical importance of this finding.

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

  • A. Adell
  • Psychology
    IDrugs : the investigational drugs journal
  • 2010
Results from phase II clinical trials have reported improvement in depression and anxiety symptoms after 6 weeks of treatment, and Lu-AA21004 was generally well tolerated, with adverse events related to sexual dysfunction occurring in a lower number of patients receiving Lu- AA21004 compared with venlafaxine.

A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder

It is shown that Lu AA21004 was effective in preventing relapse of MDD and was well tolerated as maintenance treatment.

Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine.

Whether paroxetine inhibits the human norepinephrine transporter in addition to the human serotonin (5-HT) transporter in patients with major depressive disorder is examined and this action may contribute to the broad therapeutic efficacy of parxetine in the treatment of depression, panic disorder, social anxiety disorder, posttraumatic stress disorder, and generalized anxiety disorder.